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Abstract
Lenalidomide is an effective therapy against malignant plasma cells and a potent agent against proinflammatory and 
proangiogenic cytokines. The use of lenalidomide in POEMS (polyneuropathy, organomegaly, endocrinopathy, monoclonal 
protein with plasma cells, skin changes) has been reported, but its benefit in long-term use is not well established. A 
55-year-old man with POEMS and debilitating polyneuropathy was treated with lenalidomide and dexamethasone 
followed by maintenance lenalidomide. He remains in haematologic remission and in complete recovery of functional 
status 3.5 years after diagnosis. This case supports the long-term use of lenalidomide in patients with POEMS syndrome. 
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Introduction
POEMS syndrome, first described by Bardwick et al., is a constellation of symptoms associated with a rare plasma cell 
disorder [1]. As described in the acronym, patients present with polyneuropathy, organomegaly (Castleman’s disease), 
endocrinopathy, monoclonal gammopathy and skin changes. Misdiagnosis of POEMS syndrome is not uncommon, as it is 
often indolent with unusual symptoms. Other accompanying clinical features and laboratory findings include papilloedema, 
volume overload, sclerotic bony lesions, thrombocytosis, elevated vascular endothelial growth factor (VEGF) and tendency 
for thromboembolic events. Castleman’s disease, a lymphoproliferative disorder, is present in about 11%–30% of POEMS 
patients [2]. Elevation of angiogenic cytokines such as VEGF is thought to be the pathogenic association of Castleman’s to 
POEMS syndrome [2]. 
The treatment for POEMS syndrome is mostly derived from regimens that have shown efficacy in other plasma cell dyscrasia; 
for example, the use of autologous stem cell transplant (ASCT) in multiple myeloma patients [3]. In addition to being a 
powerful immune modulator against malignant plasma cells, lenalidomide has been shown to reduce proinflammatory 
and proangiogenic cytokines, which are known cellular disturbances in POEMS syndrome [2]. Here we describe a patient 
with POEMS syndrome who had a dramatic clinical improvement after the long-term use of lenalidomide without an ASCT. 
Methods 
A 55-year-old man presented with progressive polyneuropathy over a one-year period. He was initially diagnosed with 
chronic inflammatory polyneuropathy. He received rituximab, high-dose intravenous immunoglobulin and approximately 
one month of dexamethasone without any improvement. He also received two cycles of rituximab, cyclophosphamide, 
adriamycin, vincristine and prednisone after a diagnosis of Castleman’s disease. He was transferred to our institution due 
to progressive severe motor dysfunction. 
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Physical examination was remarkable for skin 
discoloration, pitting of the nail beds and profound 
motor deficit (Fig. 1a). 
His only appreciable movement on examination was 
left second finger flexion. Laboratory studies revealed 
hypothyroidism and hypogonadism. Serum protein 
electrophoresis showed the presence of monoclonal 
protein. Serum lambda light chain was elevated. HIV, 
hepatitis B, HHV-8 and EBV were negative. VEGF was 
not performed. Other relevant laboratory data and 
physical exam findings are shown in Table 1. 
A computed tomography scan of the chest and 
abdomen showed diffuse body wall oedema, 
periportal oedema, ascites, bilateral pleural effusions 
and multiple retroperitoneal and para-aortic lymph 
nodes including an enlarged portal caval lymph 
node measuring 4.9×4.3 cm. Biopsy of the dominant 
portal caval lymph node demonstrated sheets of 
mature and atypical plasma cells with rare germinal 
centres (Fig. 1b,c), hyalinized blood vessels and HHV8 
negative consistent with HHV8 negative Castleman’s 
lymphadenopathy. 
                  Date
September 2010 September 2011 June 2013
Nail bed changes Present None None
Hyperpigmentation Present None None
Oedema ++++ Trace None
Performance status (ECOG) 4 2 1
IgG (600–1500 mg/dl) 1470 204 594
IgA (82–453 mg/dl) 186 38.5 122
Kappa (3.3–19.4 mg/dl) 60.8 <2.7 <2.7
Lambda (5.7–26.3 mg/dl) 118.00 <2.35 5.37
K/L ratio 0.52 Not calculated Not calculated
Beta 2 microglobulin (0.60–2.11 mg/l) 4.9 4.5 3.1
Monoclonal protein IgG lambda (mg/dl) 775 25 73
Bone marrow 10% plasma cells – –
Cytogenetics Normal – –
VEGF (31–86 pg/ml) – 74 <31
TSH (0.55–4.78 μIU/ml) 19.257 5.629 2.133
Testosterone, total (241–827 ng/dl) 55 624 457
Free testosterone (4.00–27.00 pg/ml) 0.1 20.3 –
24-h urine immunofixation Negative Negative Negative
Respiratory status Tracheostomy 40% FiO2 2L oxygen Room air; tracheostomy closed
Motor polyneuropathy Flaccid muscle weakness Ambulate with assistance Ambulate without assistance
Figure 1: (a) Picture taken at diagnosis. (b) Haematoxylin and eosin stains at 40× 
demonstrating sheets of mature and atypical plasma cells with rare germinal 
centres. (c) CD138 stain indicating plasma cells. (d) Picture taken 3 years after 
starting treatment.
Table 1: Progression of clinical features following therapy in a patient with POEMS syndrome
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Bone marrow biopsy showed a mildly increased predominance of plasma cells producing lambda light chains (10% by 
CD138 immunostain). Electromyography demonstrated severe sensory motor neuropathy with prominent features of 
demyelination and secondary axonal degeneration. The patient had to be intubated for neuromuscular respiratory failure 
and eventually received a tracheotomy.
Results
The patient received five sessions of plasmapheresis without any improvement. He was then started on lenalidomide 
(25 mg, days 1–21) and dexamethasone (40 mg weekly) in October 2010. The lenalidomide dose was reduced (15 
mg, days 1–21 every 28 days) after hospitalization for neutropenic fever and bacteraemia. With intensive physical and 
occupational therapy, there was steady improvement of the patient’s motor function. After four cycles of treatment, his 
lambda light chain normalized. Monoclonal protein declined to 5.2 mg/dl from 775 mg/dl. He was evaluated for ASCT 
but unfortunately failed stem cell mobilization. After 12 months of treatment, his respiratory function returned close to 
baseline. Testosterone and thyroid function normalized and there was resolution of lymphadenopathy. His treatment was 
switched to lenalidomide alone 5 mg daily after 15 months of combination therapy.
His clinical symptoms continued to recover; in particular, his motor function made the most remarkable recovery. He was 
able to ambulate and performed get-up-and-go without any assistance (Fig. 1d). In addition to regaining his functional 
capabilities, several early physical findings, such as the nail bed changes and anasarca, were completely resolved. The 
trends in his laboratory data are shown in Table 1. At the time of manuscript submission, he remains on lenalidomide 
single agent at 5 mg daily.
Discussion
The recent advancement in the understanding of POEMS’s pathogenesis has given new insights into developing a novel 
therapeutic strategy [4]. Proangiogenic cytokine, such as VEGF, is believed to play a central role in the clinical manifestations 
of POEMS syndrome and Castleman’s disease. VEGF, likely originating from abnormal plasma cells, has been associated 
with vasopermeability, leading to the transudate effusions commonly seen in these patients [2]. 
Management of POEMS is largely derived from management of other plasma cell dyscrasias, specifically multiple myeloma. 
While there is no standard of care treatment for patients with POEMS, high-dose chemotherapy with ASCT has routinely 
been used in eligible patients [3]. D’Souza et al. recently published a long-term outcome study of POEMS patients who 
underwent ASCT [5]. The 5-year progression-free survival (PFS) and overall survival (OS) were 75% and 94%, respectively, 
with a median follow-up of 45 months. Our patient failed to mobilize stem cells, likely due to exposure to the initial 
chemotherapy predating the POEMS diagnosis. 
While there has been use of novel agents, such as bortezomib and lenalidomide [6–8], the length of treatment is not well 
established for POEMS patients who are not ASCT candidates, and there is limited experience in the use of maintenance 
therapy. Our rationale of maintenance strategy is derived from the observed PFS and OS benefits in multiple myeloma 
patients receiving maintenance lenalidomide [9]. 
The treatment for POEMS syndrome is certainly evolving. We are developing new therapeutic strategies as we begin to 
understand the underlying mechanism of this complex disease. The shared characteristics with other plasma cell dyscrasias 
provided the backbone for our current treatment strategy for this rare syndrome. Use of lenalidomide and dexamethasone 
and the maintenance single-agent lenalidomide has markedly improved our patient’s symptoms and functional status.  
In conclusion, while further study is required to establish its role in routine practice, long-term use of lenalidomide is a 
viable treatment option for patients with POEMS syndrome.
 
Learning Points
•	 Lenalidomide and dexamethasone provided a substantial response in a patient with POEMS.
•	 Long-term use of lenalidomide in POEMS is feasible.
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